Matar F, Welter-Frost A. Management of Iatrogenic Atrial Septal Defects in the Era of Large-Bore Transcatheter Mitral Valve Therapies.
CARDIOVASCULAR REVASCULARIZATION MEDICINE 2020;
31:83-88. [PMID:
33339771 DOI:
10.1016/j.carrev.2020.11.019]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2020] [Revised: 07/14/2020] [Accepted: 11/18/2020] [Indexed: 11/25/2022]
Abstract
Several case reports described acute and subacute decompensations that were reversed after percutaneous interatrial septal defect (ASD) closure. At least 30% of patients post MitraClip will continue to have a persistent ASD at 1 year. Few retrospective studies described various echocardiographic associations with persistent ASD but there is no conclusive evidence that it is the cause of a poor outcome. Conclusion: At this time routine closure of ASD post MitraClip is not recommended unless there is hemodynamic decompensation that cannot be explained by other factors.
Collapse